Efferon, a biotech company that develops hemoadsorption devices to remove endotoxins and excessive inflammatory mediators from the bloodstream, has raised €4.3 million from existing private investors in the DACH region.
The devices were first developed for critical care, including sepsis and septic shock, and are approved and used across Europe. More than 30,000 treatments have been performed with them, and they are distributed in 46 countries. Efferon is now looking beyond intensive care, targeting systemic inflammation in chronic disease and healthy aging.
The funding will support commercial expansion of products including Efferon LPS and Efferon NEO in Europe, India and Latin America. It will also go towards growing the company's network of 21 distributors, continuing regulatory work and strengthening its clinical evidence base.
The company said revenue exceeded €1.1 million in 2025. It expects revenue from its intensive care products to reach about €5 million in 2027. Outpatient products could add up to €3 million, subject to successful registration.
"The new investment will support R&D, including the development of new devices and research into applications of the technology in adjacent medical fields," said Dima Romashin, Co-Founder and CEO. He added that the money will help expand the distributor network, train medical teams and build clinical evidence. "These results should lay the foundation for a full Series A round and further progress along the regulatory pathway in the United States," he said.
In India, Efferon plans to pair commercial distribution with systematic collection of real-world data. The work will look at how the technology fits into clinical workflows, how medical teams are trained, and what helps or hinders adoption. The findings will inform a model for introducing hemoadsorption in other new healthcare markets.
